People with diabetes have been hit with a five-month shortage of a vital medication. The Tresiba FlexTouch U100 insulin pen, which is manufactured by global pharmaceutical giant Novo Nordisk, is ...
PLAINSBORO, N.J., Sept. 25, 2015 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration (FDA) approved the new drug application for ...
PLAINSBORO, N.J., Jan. 26, 2016 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, today announced the availability of its newest insulin, Tresiba® (insulin degludec injection), a ...
Adults with type 2 diabetes treated with Tresiba® (insulin degludec injection) had a significant reduction in A1C and a 30% lower rate of hypoglycaemic episodes after starting basal insulin This ...
Novo Nordisk announced that the Food and Drug Administration (FDA) has approved an expanded use for Tresiba (insulin degludec) injection to improve glycemic control in children and adolescents with ...
Bagsværd, Denmark, 21 January 2013 – Novo Nordisk today announced that the European Commission has granted marketing authorisations for Tresiba® (insulin degludec) and Ryzodeg® (insulin ...
Novo Nordisk announced the launch of Tresiba (insulin degludec) injection indicated to improve glycemic control in adults with diabetes. Novo Nordisk announced the launch of Tresiba (insulin degludec) ...
Danish pharmaceutical major Novo Nordisk, on Monday, said it would soon launch its insulin injection Tresiba (insulin degludec) in India. Novo Nordisk is the leading manufacturer of insulin in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results